BR9916893A - Treatment - Google Patents

Treatment

Info

Publication number
BR9916893A
BR9916893A BR9916893-6A BR9916893A BR9916893A BR 9916893 A BR9916893 A BR 9916893A BR 9916893 A BR9916893 A BR 9916893A BR 9916893 A BR9916893 A BR 9916893A
Authority
BR
Brazil
Prior art keywords
hepatitis
treatment
virus
vaccine
antiviral agent
Prior art date
Application number
BR9916893-6A
Other languages
Portuguese (pt)
Inventor
Gillian Frances Atkinson
Ronald James Boon
Pierre G Vandepapeliere
Martine Anne Cecil Wettendorff
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of BR9916893A publication Critical patent/BR9916893A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Patente de Invenção: "TRATAMENTO". Esta invenção forneceum pacote farmacêutico que compreende como os ingredientesativos (1) um agente antiviral ativo contra o vírus da hepatite B e(2) uma vacina para a profilaxia e/ou para o tratamento deinfecção de hepatite B, sendo os ingredientes ativos para usosimultâneo ou seq³encial. Os componentes preferidos são umanálogo de nucleosídeo como o agente antiviral, junto com umavacina para o vírus da hepatite B que compreende um antígenode superfície do vírus da hepatite B.Invention Patent: "TREATMENT". This invention provides a pharmaceutical package comprising as the active ingredients (1) an antiviral agent active against the hepatitis B virus and (2) a vaccine for the prophylaxis and / or for the treatment of hepatitis B infection, the active ingredients being for simultaneous or sequential. The preferred components are a nucleoside analogue as the antiviral agent, together with a vaccine for the hepatitis B virus that comprises a hepatitis B virus surface antigen.

BR9916893-6A 1999-01-12 1999-12-21 Treatment BR9916893A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9900630 1999-01-12
PCT/EP1999/010295 WO2000041463A2 (en) 1999-01-12 1999-12-21 Combination of hepatitis b vaccine with antiviral agents

Publications (1)

Publication Number Publication Date
BR9916893A true BR9916893A (en) 2001-11-20

Family

ID=10845878

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916893-6A BR9916893A (en) 1999-01-12 1999-12-21 Treatment

Country Status (19)

Country Link
EP (1) EP1140163A2 (en)
JP (1) JP2002534438A (en)
KR (1) KR20010090011A (en)
CN (1) CN1391482A (en)
AR (1) AR022250A1 (en)
AU (1) AU760574B2 (en)
BR (1) BR9916893A (en)
CA (1) CA2359110A1 (en)
CO (1) CO5241355A1 (en)
CZ (1) CZ20012544A3 (en)
HK (1) HK1041434A1 (en)
HU (1) HUP0105070A2 (en)
IL (1) IL144186A0 (en)
NO (1) NO20013337L (en)
NZ (1) NZ512890A (en)
PL (1) PL349347A1 (en)
TR (1) TR200102024T2 (en)
WO (1) WO2000041463A2 (en)
ZA (1) ZA200105690B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1733735B1 (en) 1998-05-22 2017-03-22 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
CA2337743C (en) 1998-07-31 2015-07-07 Yoshihiro Oka Tumor antigen based on products of the tumor suppressor gene wt1
ES2298353T3 (en) 2001-03-22 2008-05-16 International Institute Of Cancer Immunology, Inc. MODIFIED WT1 PEPTIDE.
EP1447092A4 (en) * 2001-09-28 2007-07-11 Haruo Sugiyama Methods of inducing antigen-specific t cells
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
ZA200503511B (en) 2002-10-29 2006-10-25 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
CN100443117C (en) * 2003-05-13 2008-12-17 深圳康泰生物制品股份有限公司 Hepatitis B treating vaccine prepn and its prepn process and use
US8541167B2 (en) 2004-06-03 2013-09-24 Saint Louis University Methods and compositions for vaccination
WO2008104133A1 (en) * 2007-02-28 2008-09-04 Centro De Ingeniería Genética Y Biotecnología Combination therapy for the treatment of chronic hepatitis b
US20220088188A1 (en) * 2018-12-24 2022-03-24 Grand Theravac Life Science (Nanjing) Co., Ltd. Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof
CN117120088A (en) * 2021-04-07 2023-11-24 电化株式会社 Adjuvant activity enhancer and adjuvant composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0414374B1 (en) * 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Novel antigens and methods for their preparation
BR9908599A (en) * 1998-03-09 2000-11-14 Smithkline Beecham Biolog Combined vaccine compositions

Also Published As

Publication number Publication date
CO5241355A1 (en) 2003-01-31
CN1391482A (en) 2003-01-15
CZ20012544A3 (en) 2002-01-16
WO2000041463A3 (en) 2000-11-09
NZ512890A (en) 2003-09-26
AR022250A1 (en) 2002-09-04
NO20013337L (en) 2001-08-17
KR20010090011A (en) 2001-10-17
CA2359110A1 (en) 2000-07-20
AU2100900A (en) 2000-08-01
AU760574B2 (en) 2003-05-15
WO2000041463A2 (en) 2000-07-20
IL144186A0 (en) 2002-05-23
EP1140163A2 (en) 2001-10-10
ZA200105690B (en) 2002-09-25
PL349347A1 (en) 2002-07-15
JP2002534438A (en) 2002-10-15
HK1041434A1 (en) 2002-07-12
TR200102024T2 (en) 2001-12-21
NO20013337D0 (en) 2001-07-05
HUP0105070A2 (en) 2002-04-29

Similar Documents

Publication Publication Date Title
TWI317735B (en) Methods and compositions for treating hepatitis c virus
BR9916893A (en) Treatment
TR199903053T2 (en) Benzimidazole trevleri.
BR0011433B1 (en) IMMEDAZOKININE COMPOUNDS REPLACED WITH SULFONAMIDE AND SULFAMIDE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
BR0206614A (en) Compound, pharmaceutical composition, method for inhibiting rna-dependent rna viral polymerase and / or inhibiting rna-dependent rna viral replication, method for treating an rna-dependent rna viral infection, and use of a compound
BR0107972A (en) Use of a hiv tat, hiv nef, or hiv tat protein or polynucleotide attached to a hiv nef protein or polynucleotide (nef-tat), and a hiv gp120 protein or polynucleotide, method for immunizing a hiv human being against hiv, and vaccine composition for human use
BR0209658A (en) 4-Amino-5-phenyl-7-1-cyclobutyl-pyrrolo [2,3-d] pyrimidine derivatives
BR9811121A (en) Product, pharmaceutical composition, and use of a product
HRP20040059B1 (en) Treatment of nail infections with no
AR002255A1 (en) A COMPOSITION THAT INCLUDES A FORMULATION OF MICROFLUIDIZED ANTIGEN AND USES OF SUCH FORMULATION.
BR0108435A (en) Formulation and use of low dose entecavir
NO20034204D0 (en) Pharmaceutical combinations for the treatment of cancer
AR030068A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAINFUL, INFLAMMATORY AND ULCEROUS CONDITIONS OF HUMED EPITELIAL SURFACES AS FOR EXAMPLE MUCOSITIS, STOMATITIS AND BEHCET SYNDROME
HUP9904092A2 (en) Pharmaceutical composition for treatment hiv and cancer and process for producing it
HUP0202502A2 (en) Peptides that block viral infectivity and methods of use thereof
ES2188995T3 (en) USE OF AN INHIBITOR OF THE H +, K + -ATPASA IN THE TREATMENT OF NASAL POLYPS.
ES2041243T3 (en) APPLICATION OF AT LEAST ONE ACTIVE INHIBITOR OR DESTRUCTIVE PRINCIPLE OF AT LEAST ONE LIVING SOLE OR VIRUS.
BR0317539A (en) Methods and compositions for treating herpes virus infections using selective cyclooxygenase-2 inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents
BR0206775A (en) Use of a drug to treat an HIV-infected individual by combining immunization with structured interruption of antiretroviral treatment
ATE395064T1 (en) COMBINATION PREPARATIONS OF 3-N-FORMYLHYDROXYLAMINOPROPYLPHOSPHONY ACID DERIVATIVES OR 3-N-ACETYLHYDROXYLAMINOPROPYLPHOSPHONY ACID DERIVATIVES WITH SPECIAL PHARMACEUTICAL ACTIVE INGREDIENTS
NO20055243L (en) Interferon beta in severe acute respiratory syndrome (SARS)
ATE253938T1 (en) PHARMACEUTICAL COMBINATION OF ANTIVIRAL ACTIVE INGREDIENTS
BR9809127A (en) Combination, pharmaceutical formulation, process for treating HIV infection in an infected animal, use of (-) - (1s, 4r) -4- [2-amino-6- (cyclopropyl amino) -9h-purin-9 -il) -2-cyclopentene-1-methanol, and, patient package
CL2004001291A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES CARBOCICLIC AND HETEROCICLIC COMPOUNDS; AND ITS USE FOR THE TREATMENT OR PROFILAXIS OF INFLUENZA INFECTION.
AR025340A1 (en) PHARMACEUTICAL COMPOSITIONS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O E 7O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.